INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 417m ago
HOUSE PTR16m ago
SEC 13F16m ago
ROBINHOOD CHAIN16m ago
SEC FORM 4/Open-market saleVerified data

Chapman Rowan E sold NTRA

Director · Natera, Inc. · Common Stock

Side
SELL
Value
$89K
Shares
366
Price
$243.39
Executed
Dec 5, 2025
Disclosed
Dec 9, 2025
Disclosure timeline4 days from execution to publication · legal deadline 2 business days
Dec 5 executedDec 9, 2025 disclosed

NTRA · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
33/ 100 · ELEVATED
Methodology →
  • Transaction type+12 / 20

    Open-market sale

  • Relative size+8 / 25

    $89K reported value · 6.0% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering+5 / 15

    1 other actor traded the same direction within 14 days

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · NTRA

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    13
    MS
    Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS
    NTRANatera, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$49K
    120 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    13
    MS
    Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS
    NTRANatera, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$50K
    120 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    16
    BB
    Brophy Michael BurkesCHIEF FINANCIAL OFFICER
    NTRANatera, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$184K
    470 sh
    		Nov 3, 2026Nov 4, 2026
    traded Nov 3, 2026
    		+1dSEC FORM 4

    Evidence

    16
    MS
    Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS
    NTRANatera, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$164K
    410 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    13
    MS
    Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS
    NTRANatera, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$3,494
    9 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    16
    MS
    Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS
    NTRANatera, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$100K
    240 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    19
    CL
    Chapman Steven LeonardDirector, CEO AND PRESIDENT
    NTRANatera, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$366K
    914 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    16
    RD
    Rabinowitz DanielSEC. AND CHIEF LEGAL OFFICER
    NTRANatera, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$134K
    334 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    16
    MS
    Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS
    NTRANatera, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$81K
    200 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    13
    BB
    Brophy Michael BurkesCHIEF FINANCIAL OFFICER
    NTRANatera, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$3,104
    8 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    16
    BB
    Brophy Michael BurkesCHIEF FINANCIAL OFFICER
    NTRANatera, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$127K
    317 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    13
    SJ
    Sheena JonathanDirector, CO-FOUNDER
    NTRANatera, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$1,165
    3 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    16
    FJ
    Fesko JohnPRESIDENT, CHIEF BUS. OFFICER
    NTRANatera, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$118K
    295 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    22
    CL
    Chapman Steven LeonardDirector, CEO AND PRESIDENT
    NTRANatera, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$1.19M
    2,866 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    16
    MS
    Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS
    NTRANatera, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$166K
    408 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    16
    MS
    Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS
    NTRANatera, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$176K
    432 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    19
    MS
    Moshkevich SolomonPRESIDENT, CLINICALDIAGNOSTICS
    NTRANatera, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$316K
    760 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    13
    RD
    Rabinowitz DanielSEC. AND CHIEF LEGAL OFFICER
    NTRANatera, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$2,717
    7 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    13
    SJ
    Sheena JonathanDirector, CO-FOUNDER
    NTRANatera, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$44K
    109 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    19
    RM
    Rabinowitz MatthewDirector, EXECUTIVE CHAIRMAN
    NTRANatera, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$293K
    731 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001786240-25-000007
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Dec 5, 2025
    Published
    Dec 9, 2025
    Ingested by INSIDER
    Nov 5, 04:28 UTC
    Last re-read
    Nov 5, 04:28 UTC

    Extracted facts

    Filer
    Chapman Rowan E
    Role
    Director
    Transaction
    Open-market saleAs filed: “S”
    Asset
    Natera, Inc.
    Ticker
    NTRA
    Shares
    366
    Price per share
    $243.39
    Value
    $89,081
    Execution date (reported)
    Dec 5, 2025
    Owned after transaction
    5,777 shares
    Days from execution to publication
    4

    Calculation

    Value = shares × reported price per share

    • Shares: 366
    • Price: $243.39

    = $89,081

    What this establishes

    Chapman Rowan E filed this Form 4 reporting a open-market sale of NTRA on Dec 5, 2025. It became public on Dec 9, 2025. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director
    Chapman Rowan Ecik:0001786240
    Issuer
    Natera, Inc.cik:0001604821

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.